In vitro assessment of recombinant, mutant immunoglobulin G anti-D devoid of hemolytic activity for treatment of ongoing hemolytic disease of the fetus and newborn

Research output: Contribution to journalJournal articleResearchpeer-review

A specific treatment for ongoing hemolytic disease of the fetus and newborn (HDFN) due to anti-D would be very attractive. One approach could be administration to the mother of nonhemolytic anti-D, which by crossing the placenta can block the binding of hemolytic maternal anti-D.
Original languageEnglish
Issue number1
Pages (from-to)12-9
Number of pages8
Publication statusPublished - 1 Jan 2008

    Research areas

  • Animals, Antibodies, Anti-Idiotypic, Antibody-Dependent Cell Cytotoxicity, CHO Cells, Chemiluminescent Measurements, Cricetinae, Cricetulus, Erythroblastosis, Fetal, Female, Hemolysis, Humans, Immunoglobulin G, Immunotherapy, Monocytes, Mutation, Recombinant Proteins, Respiratory Burst, Rho(D) Immune Globulin

ID: 35155214